Alkermes (ALKS) Liabilities from Discontinued Operations (2022 - 2023)
Alkermes' (ALKS) quarterly Liabilities from Discontinued Operations came in at 4500000.0 in Q4 2023, down 66.77% year-on-year from 13542000.0 in Q4 2022, and down 66.77% on a QoQ basis from 13542000.0 in Q4 2022.
Alkermes (ALKS) Liabilities from Discontinued Operations (2022 - 2023) Analysis & Trends
Alkermes (ALKS) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 4500000.0 in Q4 2023.
- On a quarterly basis, Liabilities from Discontinued Operations fell 66.77% year-over-year to 4500000.0 in Q4 2023; TTM through Dec 2023 was 4500000.0, a 66.77% decrease from a year earlier, with the FY2023 full-year figure at 4500000.0, down 66.77% from the prior year.
- Liabilities from Discontinued Operations for Q4 2023 stood at 4500000.0, down from 13542000.0 in the prior quarter.
- Over the last five years, Liabilities from Discontinued Operations for ALKS reached as high as 13542000.0 in Q4 2022 and fell as low as 4500000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 4.50 Mn |
| Dec 31, 2023 | 4.50 Mn |
| Dec 31, 2022 | 13.54 Mn |
| Dec 31, 2022 | 13.54 Mn |